- Home
- SFL vs NEO Comparison
SFL vs NEO Comparison
Compare SFL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- NEO
- Stock Information
- Founded
- SFL 2003
- NEO 2001
- Country
- SFL Bermuda
- NEO United States
- Employees
- SFL N/A
- NEO N/A
- Industry
- SFL Marine Transportation
- NEO Precision Instruments
- Sector
- SFL Consumer Discretionary
- NEO Health Care
- Exchange
- SFL Nasdaq
- NEO Nasdaq
- Market Cap
- SFL 1.0B
- NEO 1.2B
- IPO Year
- SFL N/A
- NEO 1999
- Fundamental
- Price
- SFL $7.80
- NEO $9.55
- Analyst Decision
- SFL Strong Buy
- NEO Strong Buy
- Analyst Count
- SFL 2
- NEO 10
- Target Price
- SFL $14.50
- NEO $19.44
- AVG Volume (30 Days)
- SFL 1.5M
- NEO 1.9M
- Earning Date
- SFL 05-13-2025
- NEO 04-29-2025
- Dividend Yield
- SFL 13.85%
- NEO N/A
- EPS Growth
- SFL 52.99
- NEO N/A
- EPS
- SFL 1.01
- NEO N/A
- Revenue
- SFL $894,061,000.00
- NEO $660,566,000.00
- Revenue This Year
- SFL N/A
- NEO $13.06
- Revenue Next Year
- SFL $5.63
- NEO $11.18
- P/E Ratio
- SFL $7.72
- NEO N/A
- Revenue Growth
- SFL 20.12
- NEO 11.65
- 52 Week Low
- SFL $6.78
- NEO $8.05
- 52 Week High
- SFL $14.62
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- SFL 46.04
- NEO 48.48
- Support Level
- SFL $7.47
- NEO $8.05
- Resistance Level
- SFL $7.85
- NEO $10.18
- Average True Range (ATR)
- SFL 0.38
- NEO 0.72
- MACD
- SFL 0.06
- NEO 0.16
- Stochastic Oscillator
- SFL 65.81
- NEO 70.42
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.